NORRIS MEDICINES LIMITED

Towards Change

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 14th November, 2026

To,
Department of Corporate Services (DCS-CRD)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Subject: Outcome of Board Meeting held on Saturday, 14th November, 2026 pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Scrip Code: **524414**

Dear Sir/ Madam,

With reference to above captioned subject, pursuant to Regulation 30 read with Part A of Schedule III & 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and in continuation to our letter 06th November, 2026, intimating the date of Board Meeting of Norris Medicines Limited ("Company"), we would like to inform you that the Board of Directors at their Meeting held today i.e. Saturday, 14th November, 2026 inter- alia considered and approved the Unaudited Financial Results along with Limited Review Report for the quarter and half-year ended September 30, 2026.

A copy of the Unaudited Financial Results along with the Limited Review Report of the Auditors thereon issued in this regard is attached as **Annexure I.**

We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations.

Board meeting's commencement time: **05:00 PM**

Board meeting's concluded time: **05:30 PM**

Kindly take the same on your record and acknowledge receipt of the same.

Thanking you.

FOR NORRIS MEDICINES LIMITED

VIMAL D SHAH

Digitally signed by VIMAL D SHAH
Date: 2026.11.14 17:54:59 +05'30'

VIMAL D. SHAH
DIRECTOR
DIN-01506655

NORRIS MEDICINES LIMITED
Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.
Phone: 02646-223462 Fax 02646 -250126.
email: contact@norrispharma.com. Website: www.norrispharma.com
CIN No.,L24230GJ1990PLC086581.

Rs. In Lakhs

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026

Sl. No.	Particulars	QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	65.65	92.49	200.04	158.14	345.70	813.20
	(b) Other Income	0.00	0.00	0.08	0.00	2.46	4.54
	Total Income From Operations (Net)	**65.65**	**92.49**	**200.12**	**158.14**	**348.16**	**817.74**
2	Expenses						
	a. Cost of Materials Consumed	30.45	57.49	248.24	87.94	352.08	434.06
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	6.57	4.96	-76.27	11.53	-107.60	-3.60
	c. Employee Benfit Expenses	20.04	29.87	44.30	49.91	85.47	166.90
	d. Finance Costs	2.12	0.01	10.82	2.13	21.97	50.00
	e. Depreciation and Amortisation Expense	11.48	11.48	12.25	22.96	24.50	49.08
	f. Other expenditure	31.21	28.36	32.60	59.57	74.60	149.36
	Total Expenses	**101.87**	**132.17**	**271.94**	**234.04**	**451.02**	**845.80**
3	**Profit/ Loss before Tax (1-2)**	**-36.22**	**-39.68**	**-71.82**	**-75.90**	**-102.86**	**-28.06**
4	Tax Expense						
	a: Current Tax	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
5	**Profit / Loss after Tax**	**-36.22**	**-39.68**	**-71.82**	**-75.90**	**-102.86**	**-28.06**
6	**Other Comprehensive Income**						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensice Income for the period	-36.22	-39.68	-71.82	-75.90	-102.86	-28.06
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.36	-0.40	-0.72	-0.76	-1.03	-0.28

For NORRIS MEDICINES LIMITED

Managing Director

NORRIS MEDICINES LIMITED • Ankleshwar

STATEMENT OF ASSETS AND LIABILITIES

	As At 30.09.2026 Un audited	As At 31.03.2026 (Audited)
A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	455.71	478.66
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.95	0.95
ii) Loans	10.84	10.61
iii) Others	39.92	41.71
e) Non Current Tax Assets (Net)	90.40	90.40
f) Other Non Current Assets	85.94	85.33
TOTAL NON CURRENT ASSETS	**683.75**	**707.66**
2. Current Assets		
a) Inventories	459.43	398.43
b) Financial Assets		
i) Trade Receivables	72.63	117.40
ii) Cash and Cash Equivalents	7.00	2.16
iii)Bank Balance other than"b" above.		
iv)Loans		
v) Others	90.09	63.28
TOTAL CURRENT ASSETS	**629.16**	**581.28**
TOTAL ASSETS	**1312.91**	**1288.94**
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.58	992.58
b) Other Equity	-2583.29	-2,507.39
Total Equity	**-1590.71**	**-1514.81495**
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1866.22	1,851.22
b)Provisions		
c) Deferred Tax Laibilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	**1866.22**	**1851.22**
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	302.31	302.31
ii) Trade payables	285.88	262.19
iii) Other financial liabilities	171.33	116.29
b) Other Current Liabilities	0.00	-
c) Provisions	277.90	271.76
Total Current Liabilities	**1037.41**	**952.54**
TOTAL EQUITY AND LIABILITIES	**1312.91**	**1288.94**

Notes:

1) The above Unaudited Fianacial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.11.2026. The above results have been subjected to Audit by the Statutory Auditors of the company .

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Reguirements) Regulation,2015 and SEBI circular dated 05.07.2016.

3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.09.2026

5) Previous year/ period have been regrouped / rearranged whereever necessary to make them comparable with current period figures.

For Norris Medicines Limited

Vimal D Shah
Managing Director

NORRIS MEDICINES LIMITED • Ankleshwar

Date: 14.11.2026

Place:Ankleshwar

NORRIS MEDICINES LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 30th,September 2026

	Particulars	30-09-2026	31.03.2026
		Rs.Ps	Rs. Lakhs
(A)	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit/Loss before tax and extraordinary items	- 75.90	- 28.06
	Adjustments for :		
	Depreciation & Amortisation	22.96	49.08
	Deferred Tax Liability	-	-
	Interest Income	-	- 2.00
	Interest Paid	2.13	50.00
	Profit/Loss on Investment in bonds	-	-
	Profit/Loss on sale of Fixed Assets	-	-
	Other Non Operating Income	-	-
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	**(50.81)**	**69.02**
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	44.77	23.50
	Increase/Decrease in Inventories	(61.00)	14.38
	Increase/Decrease in Loans & Advances	(26.82)	13.32
	Trade Payables and Other Liabilities	84.87	- 62.46
	Net cash from operations before taxation	**41.82**	**- 11.26**
	Tax Paid	-	-
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	**41.82**	**- 11.26**
	Extra Ordinary Item	-	-
	NET CASH FROM OPERATING ACTIVITIES	**(8.99)**	**57.76**
(B)	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase of Fixed Assets	-	- 0.96
	Sale of Fixed Assets	-	-
	Investments Made during the year	-	-
	Long Term Advances	0.96	- 9.10
	Receipt from Investment	-	-
	Interest Income	-	2.00
	Dividend Received	-	-
	Profit/Loss on sale of bonds	-	-
	Net Cash used in Investing Activities (B)	**0.96**	**- 8.06**
(C)	**CASH FLOW FROM FINANCING ACTIVITIES:-**		
	Share Capital	-	-
	Borrowings	15.00	- 1.52
	Interest paid	(2.13)	- 50.00
			-
	Net Cash Used in Financing Activities (C)	**12.87**	**- 51.52**
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	4.84	- 1.82
	Cash and Cash equivalents - Opening balance	2.16	3.98
	Cash and cash equivalents - Closing balance	7.00	2.16
		(4.84)	**1.82**
	Component of Cash & Cash Equilents		
	Cash on hand	0.76	0.96
	With Banks in Current Accounts	6.24	1.20
		7.00	**2.16**

For NORRIS MEDICINES LIMITED

Managing Director

NORRIS MEDICINES LIMITED • Ankleshwar

BAHEDIA & ASSOCIATES

Chartered Accountants

SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412

CA. B. L. Bahedia
(FCA., LL.B., D.T.P., B.Com.)

Mobile No. : +91 98241 36264, 97252 20412
E-mail : bbahedia@yahoo.com/gmail.com

"Limited Review Report"

To,
The Board of Directors of NORRIS MEDICINES LIMITED.

We have reviewed the accompanying statement of unaudited financial results of NORRIS MEDICINES LIMITED, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the quarter and six months ended 30th September, 2026. This statement is the responsibility of the Company's Management and has been approved by the Audit Committee and Board of Directors in their meeting held on 14/11/2026. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed Standard on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matter that might be identified in an Audit, and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)

(CA. B.L. BAHEDIA)
PROPRIETOR
(M.NO.048066)
UDIN: - 26048066EMFFRZ3329

PLACE: ANKLESHWAR
DATE: 14/11/2026

BAHEDIA & ASSOCIATES • CHARTERED ACCOUNTANTS • Ankleshwar-2 M.NO.048066